Lfb S.A Dba Hem Patent-Cliff Exposure & CMS Drug Spending Portfolio

Lfb S.A Dba Hem (US): 1 reconciled FDA prescription therapies, $27.3M 2024 CMS Part D & Medicaid spend, and $5,320 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$27.3M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$27.3M
California HCAI SB 17 FilingsSpecialty launch notice ($5,320 intro WAC)